About BAC
BAC BV was established in 1995 as a Unilever subsidiary. In 2002 Unilever Ventures provided the support to set up a new business in affinity ligands. They facilitated the start of BAC's spin-off, thereby capitalising on the large investments made by the Unilever Group in the discovery and production of single domain antibody fragments over the past ten years.
In 2005 BAC completed an external private financing round to enable the company to continue development of new solutions for lab scale separations and to advance its lead products toward launch for large scale use in pharmaceutical processes.
In 2008 BAC completed a Series B financing round to support the further development of its own pipeline of affinity products. The Company is now focused on three main business areas: custom ligand design, supply of ligands for commercial-scale bioprocessing and supply of ready-to-use affinity products for life science research.
BAC has a dedicated and experienced team, its own R&D and manufacturing facilities, and a renowned Supervisory Board
